drugset / Trial / NCT01172717
Study of Panitumumab in the Treatment of Carcinoid Syndrome
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary hypothesis of this study is that panitumumab, an inhibitor of the epidermal growth factor receptor (EGFR), is an effective treatment for carcinoid syndrome in people who fail or do not adequately respond to octreotide or other supportive therapies.
Timeline
- Start
- 2013-07
- Primary completion
- 2013-07
- Completion
- 2013-07
Outcome
Outcome not reported
Stopped: “Study never began”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Panitumumab | Monoclonal antibody | 9 mg/kg | Intravenous |